|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Zymergen
gptkb:Grail,_Inc.
gptkb:Edico_Genome
Blue Bee
Verinata Health
|
|
gptkbp:ceo
|
gptkb:Francis_de_Souza
|
|
gptkbp:employees
|
over 7,000
|
|
gptkbp:founded
|
gptkb:1998
|
|
gptkbp:founder
|
gptkb:David_Walt
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Illumina Technologies
|
|
gptkbp:industry
|
gptkb:Database_Management_System
|
|
gptkbp:market_cap
|
$40 billion (2021)
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:temple
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:NHS_Genomic_Medicine_Service
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Illumina_Accelerator
gptkb:Novartis
|
|
gptkbp:products
|
DNA sequencing systems
|
|
gptkbp:research_focus
|
Bioinformatics
Genetic disorders
Health economics
Reproductive health
Clinical trials
Epigenomics
Metagenomics
Proteomics
Synthetic biology
Transcriptomics
Infectious diseases
Personalized medicine
Gene editing
Pharmacogenomics
Clinical genomics
Population genomics
Rare diseases
Cancer genomics
Regulatory science
Translational genomics
Microbiome analysis
Single-cell genomics
Agrigenomics
Cell-free DNA analysis
Ethical implications of genomics
|
|
gptkbp:revenue
|
$3.24 billion (2020)
|
|
gptkbp:symbol
|
gptkb:ILMN
|
|
gptkbp:technology
|
Next-generation sequencing
|
|
gptkbp:bfsParent
|
gptkb:Illumina
|
|
gptkbp:bfsLayer
|
4
|